Shots:

• The CONCLUDE study assess the hypoglycemic risk with Tresiba (qd) vs insulin glargine U300 (qd) in 1-609 patients with T2D with/out oral anti-diabetic drugs- for 36wks. maintenance period and a total treatment period of up to 88wks.
• The CONCLUDE study result: reduction in the rate of severe hypoglycemia & nocturnal symptomatic hypoglycemia (80% & 37% vs 62% & 43%) during maintenance period & total treatment period- reduction in the overall risk of hypoglycemia and significantly lower HbA1c- required insulin dose (67U vs 73U)
• Tresiba is basal insulin- providing a duration of action beyond 42hrs. with a flat and stable glucose-lowering effect- received first regulatory approval in Sept’2012 and is approved therapy in 80+ countries globally

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Behance